Business ❯ Pharmaceuticals ❯ Drug Companies
Acquisitions Cancer Drugs Generic Competition Patent Protection Debt Financing Acquisition Johnson & Johnson
Two remaining Phase 3 studies in atrial fibrillation and secondary stroke prevention continue, with topline results expected in 2026.
